SHANGHAI – Epimab Biotherapeutics Inc., of Shanghai, now has $25 million in its coffers to put its lead candidate into clinical development, a bispecific antibody for oncology. The series A investors hail from China, the U.S. and the U.K., with Oriza Seed Capital taking the lead in addition to Decheng Capital, 3E Bioventures and Trend Investment Group.